NCT05038657招募中2 期
Atezolizumab in Patients With Urinary Tract Squamous Cell Carcinoma: a Single Arm, Open Label, Multicentre, Phase II Clinical Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Response to
研究概览
简要总结
Atezolizumab in patients with urinary tract squamous cell carcinoma: a single-arm, open-label, multicentre, phase II clinical trial
详细描述
AURORA is a phase II open-label trial of Atezolizumab in patients with urinary tract squamous cell carcinoma (UTSCC). UTSCC is the most common of the rare urinary tract cancer histologies, comprising 2.1-6.7% of urinary tract cancers overall. There are few data available to guide treatment decisions for UTSCC. The AURORA trial will test the hypothesis that PD-L1 inhibition with atezolizumab immunotherapy is clinically effective, tolerable and safe, in patients with urinary tract squamous cell carcinoma (UTSCC). Translational endpoints will aim to determine characteristics for responsiveness to this treatment. AURORA was developed on behalf of the International Rare Cancers Initiative (IRCI) and the National Cancer Research Institute Bladder and Renal Group.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed cancer of the urinary tract with squamous cell carcinoma histology and without any TCC component. Mixed non-TCC histology is allowed if squamous cell carcinoma is the predominant histology
- •Newly diagnosed or progressive measurable disease as defined by RECIST version 1.
- •To be considered measurable (and to be designated as a target lesion), a lesion must not have been treated with prior radiotherapy or focal ablation techniques
- •Suitable, in the judgment of the local investigator, for treatment with atezolizumab, with palliative intent
- •Adequate haematologic and end-organ function within 28 days prior to the first study treatment including:
- •Absolute neutrophil count ≥ 1.5 x109/L
- •Platelet count ≥ 100 x109/L
- •Haemoglobin ≥ 90 g/L
- •Aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase ≤ 2.5 times the institutional upper limit of normal (ULN)
- •Total bilirubin ≤ 1.5 times ULN (or ≤ 3 ULN in patients with Gilbert's syndrome)
- •Calculated creatinine clearance ≥ 20 mL/min (Cockcroft-Gault formula)
- •Up to one prior line of systemic chemotherapy for UTSCC
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- •Life expectancy ≥ 12 weeks
- •Representative formalin-fixed paraffin-embedded (FFPE) tumour sample with an associated linked-anonymised pathology report that is available for central use in translational studies
- •Able to comply with all trial procedures and processes
- •Aged 18 years or over
- •Provision of written informed consent
排除标准
- •Any component of TCC histology
- •Planned for treatment with curative intent
- •Prior systemic immunotherapy (prior intra-vesical treatments are allowed)
- •Major surgery within 30 days prior to enrolment
- •History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
- •Known hypersensitivity to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
- •Use of oral or IV steroids for 14 days prior to enrolment. Use of inhaled corticosteroids, physiologic replacement doses of glucocorticoids (i.e., for adrenal insufficiency), and mineralocorticoids (e.g., fludrocortisone) is allowed
- •Administration of a live or attenuated vaccine within 4 weeks prior to enrolment (COVID-19 vaccination is allowed)
- •Treatment with any other investigational agent within 4 weeks prior to enrolment
- •Coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, unstable arrhythmias, unstable angina or congestive cardiac failure (New York Heart Association ≥ grade 2) within 6 months prior to enrolment
- •Patients with known HIV infection or with active tuberculosis
- •Patients with known active hepatitis B virus (HBV; chronic or acute; defined as having a positive hepatitis B surface antigen [HBsAg] test) or hepatitis C. Patients with past HBV infection or resolved HBV infection (defined as the presence of hepatitis B core antibody and the absence of HBsAg) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA
- •Autoimmune disease including myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone or with controlled Type I diabetes mellitus on a stable dose of an insulin regimen are eligible for this study
- •History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. A history of radiation pneumonitis in the radiation field (fibrosis) is permitted
- •Prior allogeneic stem cell or solid organ transplant
- •Patients who are pregnant or breastfeeding
- •Patients of child-bearing potential who are not able to use a highly effective method of contraception (as detailed in section 3.6)
- •A recent or current other cancer. Current non-melanoma skin cancer, cervical carcinoma in situ, or localized prostate cancer not requiring current treatment are permissible, as is a history of a separate other malignancy having completed all active treatment ≥2 years previously
研究组 & 干预措施
Atezolizumab
Experimental
Treatment will consist of atezolizumab, by IV infusion, at a fixed dose of 1680 mg, every 28 days (day 1 of each cycle, +/- 3 days), for up to one year. Each participant will receive up to 13 doses in total.
干预措施: Atezolizumab (Drug)
结局指标
主要结局
Response to
时间窗: 36 months
To determine the clinical activity of atezolizumab in patients with incurable histologically confirmed, immunotherapy naïve UTSCC To determine the clinical activity of atezolizumab in patients with incurable histologically confirmed, immunotherapy naïve UTSCC
次要结局
- Progression free survival(36 months)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
2 期
Phase II open-label trial of atezolizumab in patients with urinary tract squamous cell carcinomarinary tract squamous cell carcinomaCancerISRCTN83474167niversity Hospital Southampton NHS Foundation Trust36
已完成
2 期
Neoadjuvant Atezolizumab in Localized Bladder CancerCarcinoma, Transitional CellNCT02451423Lawrence Fong23
已完成
3 期
A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung CancerNon-Small Cell Lung CancerNCT03735121Hoffmann-La Roche438
招募中
1 期
Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial CarcinomaMetastatic MalignancyNCT05394337M.D. Anderson Cancer Center10
进行中（未招募）
1 期
International study that compares a chemotherapy regimen with atezolizumab, paclitaxel and carboplatin versus a regimen with placebo, paclitaxel and carboplatin in patients affected by advanced or recurrent endometrial cancer .EUCTR2018-001072-37-DEIRCCS - Istituto di Ricerche Farmacologiche Mario Negri550